PL2994126T3 - Kombinacja inhibitora kinazy pi3 z paklitakselem do stosowania w leczeniu lub zapobieganiu nowotworowi złośliwemu głowy i szyi - Google Patents

Kombinacja inhibitora kinazy pi3 z paklitakselem do stosowania w leczeniu lub zapobieganiu nowotworowi złośliwemu głowy i szyi

Info

Publication number
PL2994126T3
PL2994126T3 PL14731782T PL14731782T PL2994126T3 PL 2994126 T3 PL2994126 T3 PL 2994126T3 PL 14731782 T PL14731782 T PL 14731782T PL 14731782 T PL14731782 T PL 14731782T PL 2994126 T3 PL2994126 T3 PL 2994126T3
Authority
PL
Poland
Prior art keywords
paclitaxel
cancer
neck
prevention
head
Prior art date
Application number
PL14731782T
Other languages
English (en)
Inventor
Samit Hirawat
Cristian MASSACESI
Emmanuelle DI TOMASO
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PL2994126T3 publication Critical patent/PL2994126T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Dermatology (AREA)
PL14731782T 2013-05-07 2014-05-06 Kombinacja inhibitora kinazy pi3 z paklitakselem do stosowania w leczeniu lub zapobieganiu nowotworowi złośliwemu głowy i szyi PL2994126T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1354211 2013-05-07
PCT/IB2014/061239 WO2014181252A1 (en) 2013-05-07 2014-05-06 Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck
EP14731782.0A EP2994126B1 (en) 2013-05-07 2014-05-06 Combination of a pi3 kinase inhibitor with paclitaxel for use in the treatment or prevention of a cancer of the head and neck

Publications (1)

Publication Number Publication Date
PL2994126T3 true PL2994126T3 (pl) 2018-11-30

Family

ID=49620017

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14731782T PL2994126T3 (pl) 2013-05-07 2014-05-06 Kombinacja inhibitora kinazy pi3 z paklitakselem do stosowania w leczeniu lub zapobieganiu nowotworowi złośliwemu głowy i szyi

Country Status (20)

Country Link
US (2) US20160082012A1 (pl)
EP (1) EP2994126B1 (pl)
JP (2) JP6643978B2 (pl)
KR (1) KR102356393B1 (pl)
CN (1) CN105228611B (pl)
AU (1) AU2014264318B2 (pl)
BR (1) BR112015027047A2 (pl)
CA (1) CA2909448C (pl)
CY (1) CY1120693T1 (pl)
DK (1) DK2994126T3 (pl)
ES (1) ES2688464T3 (pl)
HR (1) HRP20181489T1 (pl)
HU (1) HUE039393T2 (pl)
LT (1) LT2994126T (pl)
MX (1) MX2015015475A (pl)
PL (1) PL2994126T3 (pl)
PT (1) PT2994126T (pl)
RU (1) RU2672555C2 (pl)
SI (1) SI2994126T1 (pl)
WO (1) WO2014181252A1 (pl)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2660B1 (en) * 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
WO2009155659A1 (en) * 2008-06-27 2009-12-30 The University Of Queensland Combination therapy
WO2012118978A1 (en) * 2011-03-03 2012-09-07 The Regents Of The University Of Colorado, A Body Corporate Methods for treating oncovirus positive cancers

Also Published As

Publication number Publication date
RU2672555C2 (ru) 2018-11-16
US20160082012A1 (en) 2016-03-24
AU2014264318B2 (en) 2017-03-16
HRP20181489T1 (hr) 2018-11-16
EP2994126B1 (en) 2018-06-20
BR112015027047A2 (pt) 2017-07-25
JP6643978B2 (ja) 2020-02-12
LT2994126T (lt) 2018-09-25
RU2015152032A (ru) 2017-06-13
JP2019131559A (ja) 2019-08-08
US20170173032A1 (en) 2017-06-22
MX2015015475A (es) 2016-03-21
CA2909448A1 (en) 2014-11-13
AU2014264318A1 (en) 2015-10-22
KR102356393B1 (ko) 2022-01-26
ES2688464T3 (es) 2018-11-02
CY1120693T1 (el) 2019-12-11
HUE039393T2 (hu) 2018-12-28
SI2994126T1 (sl) 2018-10-30
CA2909448C (en) 2021-10-26
KR20160005702A (ko) 2016-01-15
PT2994126T (pt) 2018-10-22
CN105228611B (zh) 2018-01-26
EP2994126A1 (en) 2016-03-16
JP2016518400A (ja) 2016-06-23
CN105228611A (zh) 2016-01-06
WO2014181252A1 (en) 2014-11-13
US9913846B2 (en) 2018-03-13
DK2994126T3 (en) 2018-09-24

Similar Documents

Publication Publication Date Title
IL304851A (en) Tazematostat in combination with an acceptable treatment factor for use in the treatment of cancer
HK1223089A1 (zh) 激酶抑制劑及其用途
GB2513167B (en) Tetrahydrocannabivarin for use in the treatment of nausea and vomiting
PT3004108T (pt) Derivados de pirazolo-pirrolidin-4-ona como inibidores de bet e a sua utilização no tratamento de doenças
HK1221144A1 (zh) 用於治療癌症的包含 激酶抑制劑和胞苷類似物的組合療法
HK1223304A1 (zh) 包含二甲雙胍和二氫槲皮素的藥物組合及其用於治療癌症的用途
HUE052930T2 (hu) DNQ vagy DNQ-87 alkalmazása PARP1-inhibitorral kombinációban rák kezelésére
GB201604213D0 (en) Drug combination and its use in therapy
LT3057589T (lt) (s)-pirlindolas ir jo farmaciniu požiūriu priimtinos druskos, skirti naudoti medicinoje
IL248854B (en) R-pyralindole and its pharmaceutically acceptable salts for use in medicine
HK1223014A1 (zh) 用於在預防和/或治療多動性運動障礙中使用的治療劑
IL251407A0 (en) A multivalent compound for the treatment and prevention of brain damage
HRP20181489T1 (hr) Kombinacija inhibitora pi3 kinaze s paklitakselom za uporabu u liječenju ili prevenciji raka glave i vrata
IL245998B (en) Pharmaceutical preparations for the treatment of metastatic cancer and its prevention
ZA201600894B (en) Use of 3-carboxy-n-ethyl-n,n-dimethylpropan-1-aminium or a pharmaceutically acceptable salt thereof in the prevention and treatment of diabetes
GB201312129D0 (en) Drug combination and its use in therapy
GB201312128D0 (en) Drug combination and its use in therapy
GB201312131D0 (en) Drug combination and its use in therapy
HUE047636T2 (hu) Arginin csontízületi gyulladás kezelésében és/vagy megelõzésében történõ alkalmazásra